Diagnostic and Interventional Cardiology

Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent Sapien 3 transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR. #TCT2019

News | Heart Valve Technology

October 3, 2019 – Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and ...

October 03, 2019

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

Feature | Cath Lab

Left Main Treated With PCI or CABG Have Similar Outcomes at Five Years

October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with ...

October 03, 2019

COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

News | Heart Failure

COAPT Three-year Data Show Continued Effectiveness in Heart Failure Patients

October 3, 2019 – The three-year results from the COAPT Trial demonstrated that reducing severe secondary mitral ...

October 03, 2019

Sponsored Content

ASCEND provides the tools that not only address the unique needs of each cardiovascular subspecialty and to care for patients from infancy into their golden years, they also innovates next-generation solutions and services that empower the provider community to truly transform their cardiovascular services

Feature | Information Technology

SPONSORED CONTENT: Unveiling the Future of Cardiovascular Workflow

Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...

March 21, 2024

The Boston Scientiofic Acurate Neo TAVR valve did not meet non-inferiority to the Sapien 3 valve in patients with severe aortic stenosis. #TAVR #TCT2019

News | Heart Valve Technology

New Acurate neo Self-expanding TAVR Device Does Not Meet Non-Inferiority Compared to Sapien 3

October 2, 2019 – The first randomized trial to compare the safety and efficacy of the new Boston Scientific Acurate neo ...

October 02, 2019

Videos | University of Colorado Hospital

VIDEO: Overview of University of Colorado Structural Heart Program

Interview with John Carroll, M.D., director of interventional cardiology, Robert Quaife, M.D., director of advanced ...

October 02, 2019

The Portico FDA investigational device exemption (IDE) study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems. #TAVR #TCT2019

News | Heart Valve Technology

Portico TAVR System Found Safe and Effective for High-Risk Surgical Patients

October 2, 2019 – The Abbott Portico FDA investigational device exemption (IDE) study found that 30-day safety and one ...

October 02, 2019

Sponsored Content

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability to diagnose cardiac disease with greater accuracy and precision

Feature | Cardiac Imaging

SPONSORED CONTENT: Finding the Right Solution

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...

March 05, 2024

News | Cath Lab | Dave Fornell, Editor

Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders

October 2, 2019 — Democratic presidential candidate Sen. Bernie Sanders (D-VT) was hospitalized with chest pain on Oct ...

October 02, 2019

This is a view of the Level Ex IVUS training app to help users of Philips' intravascular ultrasound system. It is integrated into a percutenous coronary intervention (PCI) training app for mobile devices that allows interventional cardiologists to perform streamlined cath lab patient case simulations, including, iFR, angioplasty and stenting. #TCT2019

News | Intra-Vascular Ultrasound (IVUS)

IVUS and iFR Video Game App Training Offered by Philips and Level Ex

October 2, 2019 — Philips Healthcare is utilizing Level Ex’s video game app design expertise to train interventional ...

October 02, 2019

This shows the TEE ultrasound imaging used to guide MitraClip procedures to treat functional mitral regurgitation.

360 Photos | 360 View Photos

360 View of the TEE Echo Workstation During a MitraClip Procedure

This 360 degree view shows staff at the University of Colorado Heart and Vascular Center performing live transesophageal ...

October 02, 2019

Sponsored Content

Blog

BLOG: Combining Local Impedance with Contact Force to Perform RF Ablation

When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...

December 11, 2023

A MitraClip case underway at the University of Colorado Hospital hybrid cath lab. Left to right are doctors John Carroll, Edward Gill and Dominik Wiktor.

Blog | University of Colorado Hospital

Highlighting Innovation at the University of Colorado Hospital Cardiology Program

I recently had the opportunity to conduct an onsite visit to the University of Colorado Hospital Heart and Vascular ...

October 02, 2019

Comparison of a STEMI coronary artery blockage pre- and post-PCI for a patient who had a 9-minute door-to-balloon time at a rural hospital that implemented a pre-hospital STEMI protocol. This article was submitted by UH Portage Medical Center about how they set up their program.

Feature | Dave Fornell, Editor

October 1, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

October 01, 2019

Khaldoon Alaswad, M.D., right, director, cardiac catheterization lab, during a complex CTO procedure at Henry Ford Hospital.

Feature | Henry Ford Hospital | Dave Fornell, Editor

Innovations in Cardiology at Henry Ford Hospital

Henry Ford Hospital thought leaders regularly speak at the cardiology conferences about new research and technology ...

October 01, 2019

Sponsored Content

Case Study | Hemodynamic Monitoring Systems

TECH BRIEF — Integrated Hemodynamic Monitoring System Helps Improve Lab Performance, Efficiency

Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...

November 14, 2023

Videos | Heart Valve Technology

VIDEO: Transcatheter Mitral Valve Interventions at Henry Ford Hospital

Marvin Eng, M.D., structural fellowship director at Henry Ford Health System, and William O'Neill, M.D., director of the ...

September 30, 2019

News | Stents Drug Eluting

Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT

The first randomized trial to compare a durable polymer drug- eluting stent to a polymer-free drug-coated stent in patients at high risk of bleeding and treated with one-month dual antiplatelet therapy (DAPT) found that both are clinically safe and effective.

September 30, 2019

News | Stents Drug Eluting

Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD

A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) is safe and effective in patients undergoing percutaneous coronary intervention (PCI) for unprotected left main coronary artery (uLMCA) disease. These findings are courtesy of the IDEAL-LM trial, which compared BP-EES plus four months of DAPT to a conventional durable polymer everolimus-eluting stent (DP-EES) followed by 12 months of DAPT.

September 30, 2019